Correction to: The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro‑entero‑pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu] Lu‑DOTATATE
- PMID: 40478513
- DOI: 10.1007/s00259-025-07378-w
Correction to: The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro‑entero‑pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu] Lu‑DOTATATE
Erratum for
-
The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE.Eur J Nucl Med Mol Imaging. 2024 Dec;52(1):291-304. doi: 10.1007/s00259-024-06863-y. Epub 2024 Sep 5. Eur J Nucl Med Mol Imaging. 2024. PMID: 39235614
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous
